Respira Technologies Inc. plans to submit an inhaler device to the Food and Drug Administration by late 2021 for authorization as nicotine replacement therapy. The nebulizer, which converts nicotine to an aerosol, aims to disrupt an estimated $618 billion market dominated by decades-old gums and patches from pharma companies as well as tobacco companies’ more recent, controversial cigarette alternatives.

“The reality is we have folks who are addicted to nicotine who never tried combustible products before,” Chief Executive Officer Mario Danek said [...] “They’re used to sleeker products, and we have that design.”